

## WEST Search History

DATE: Wednesday, March 16, 2005

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT,USOC; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L5	L2 (s)(amyloid\$ or fibrillogen\$)	0
<input type="checkbox"/>	L4	20000504	29
<input type="checkbox"/>	L3	L2 and (amyloid\$ or fibrillogen\$)	121
<input type="checkbox"/>	L2	(IAPP or ILe Ala pro pro)	455
<input type="checkbox"/>	L1	(IAPP or ILe Ala pro pro) (s) (amyloid\$ or fibrillogen\$)	0

END OF SEARCH HISTORY

## Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs
Generate OACS				

**Search Results - Record(s) 1 through 29 of 29 returned.**

☐ 1. Document ID: US 6054114 A

**Using default format because multiple data bases are involved.**

L4: Entry 1 of 29

File: USPT

Apr 25, 2000

US-PAT-NO: 6054114

DOCUMENT-IDENTIFIER: US 6054114 A

TITLE: Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro

DATE-ISSUED: April 25, 2000

**INVENTOR-INFORMATION:**

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lansbury, Jr.; Peter T.	Brookline	MA		
Han; Hogyu	Seoul			KR
Cho; Cheon-Gyu	Seoul			KR
Zhen; Weiguo	Waltham	MA		
Harper; James D.	Cambridge	MA		
Davison; Alan	West Roxbury	MA		

US-CL-CURRENT: 424/1.11; 424/9.1, 534/10, 534/12, 534/14, 534/883, 556/45

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 2. Document ID: US 6034211 A

L4: Entry 2 of 29

File: USPT

Mar 7, 2000

US-PAT-NO: 6034211

DOCUMENT-IDENTIFIER: US 6034211 A

TITLE: .beta.-sheet nucleating peptidomimetics

DATE-ISSUED: March 7, 2000

**INVENTOR-INFORMATION:**

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kelly; Jeffery W.	College Station	TX	77840	

US-CL-CURRENT: 530/317; 546/101

## ABSTRACT:

N-methylated .beta.-sheet nucleating peptidomimetics containing diarylheterocycle .beta.-turn mimics, and methods of making and using them.

13 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 3. Document ID: US 6010853 A

L4: Entry 3 of 29

File: USPT

Jan 4, 2000

US-PAT-NO: 6010853

DOCUMENT-IDENTIFIER: US 6010853 A

TITLE: Siva genes, novel genes involved in CD27-mediated apoptosis

DATE-ISSUED: January 4, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kanteti; Prasad V. S.	Boston	MA		
Ao; Zhaohui	Devon	PA		
Schlossman; Stuart F.	Newton Centre	MA		

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/91.4, 435/91.5, 536/23.1, 536/23.4, 536/23.5

## ABSTRACT:

The invention provides isolated nucleic acids molecules, designated Siva nucleic acid molecules, which encode proteins involved in immune cell apoptosis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Siva nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Siva gene has been introduced or disrupted. The invention still further provides isolated Siva proteins, fusion proteins, antigenic peptides and anti-Siva antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

16 Claims, 2 Drawing figures

Exemplary Claim Number: 1,8

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 4. Document ID: US 6010849 A

L4: Entry 4 of 29

File: USPT

Jan 4, 2000

US-PAT-NO: 6010849

DOCUMENT-IDENTIFIER: US 6010849 A

TITLE: Sequence-directed DNA binding molecules compositions and methods

DATE-ISSUED: January 4, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		
Turin; Lisa M.	Redwood City	CA		
Fry; Kirk E.	Palo Alto	CA		

US-CL-CURRENT: 435/6; 435/7.1

## ABSTRACT:

The present invention defines a DNA:protein binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

11 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 47

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWAC	Draw. D.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 5. Document ID: US 5998367 A

L4: Entry 5 of 29

File: USPT

Dec 7, 1999

US-PAT-NO: 5998367

DOCUMENT-IDENTIFIER: US 5998367 A

TITLE: Pramlintide pro H-amylin salts and compositions

DATE-ISSUED: December 7, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gaeta; Laura S. L.	La Jolla	CA		
Jones; Howard	Poway	CA		
Albrecht; Elisabeth	San Diego	CA		

US-CL-CURRENT: 514/12; 514/24, 514/866, 530/324

## ABSTRACT:

Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.

5 Claims, 3 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 6. Document ID: US 5942227 A

L4: Entry 6 of 29

File: USPT

Aug 24, 1999

US-PAT-NO: 5942227

DOCUMENT-IDENTIFIER: US 5942227 A

TITLE: Pharmaceutical compositions containing antibodies to amylin

DATE-ISSUED: August 24, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J.S.	Auckland			NZ
Greene, Jr.; Howard	Rancho Santa Fe	CA		

US-CL-CURRENT: 424/139.1; 424/141.1, 514/3, 530/387.9

## ABSTRACT:

Compositions comprising antibodies directed to amylin in a pharmaceutically acceptable carrier for use in blocking the effects of amylin.

2 Claims, 0 Drawing figures  
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

## 7. Document ID: US 5935927 A

L4: Entry 7 of 29

File: USPT

Aug 10, 1999

US-PAT-NO: 5935927

DOCUMENT-IDENTIFIER: US 5935927 A

TITLE: Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts

DATE-ISSUED: August 10, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vitek; Michael P.	East Norwich	NY		
Cerami; Anthony	Shelter Island	NY		
Bucala; Richard J.	New York	NY		
Ulrich; Peter C.	Old Tappan	NJ		
Vlassara; Helen	Shelter Island	NJ		
Zhang; Xini	Jericho	NJ		

US-CL-CURRENT: 514/12, 514/23, 514/359, 514/438, 514/439, 514/443, 514/569, 514/642, 514/647, 514/79, 514/91, 514/95, 530/300, 530/322, 536/1.11, 548/100, 548/121, 548/122

## ABSTRACT:

The present invention relates generally to methods and compositions for treating amyloidogenic diseases such as Alzheimer's disease and the development of type II diabetes, in which deposition of amyloid in organs such as the brain and pancreas interfere with neurological function and insulin release, respectively. The methods and compositions are directed toward increasing the activity of scavenger cells within the body at recognizing and removing amyloid deposits from affected tissues and organs. Scavenger cells may be targeted to amyloid deposits by means of spontaneously-occurring chemical modifications called advanced glycosylation endproducts (AGEs). Compositions are described which increase scavenger cell activity towards AGE-modified amyloid. Amyloid removal may also be enhanced by increasing AGE levels in amyloid deposits within the body by administering AGE-modified amyloid targeting agents, which after becoming situated at sites containing amyloid, subsequently attract scavenger cells to degrade attendant amyloid. These methods and associated compositions result in a decrease in the extent of amyloid deposits in tissues, reducing the attendant pathology.

9 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

## 8. Document ID: US 5869241 A

L4: Entry 8 of 29

File: USPT

Feb 9, 1999

US-PAT-NO: 5869241

DOCUMENT-IDENTIFIER: US 5869241 A

TITLE: Method of determining DNA sequence preference of a DNA-binding molecule

DATE-ISSUED: February 9, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		
Turin; Lisa M.	Redwood City	CA		
Fry; Kirk E.	Palo Alto	CA		

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2

## ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

11 Claims, 72 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 47

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 9. Document ID: US 5854204 A

L4: Entry 9 of 29

File: USPT

Dec 29, 1998

US-PAT-NO: 5854204

DOCUMENT-IDENTIFIER: US 5854204 A

TITLE: A.beta. peptides that modulate .beta.-amyloid aggregation

DATE-ISSUED: December 29, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Findeis; Mark A.	Cambridge	MA		
Benjamin; Howard	Lexington	MA		

Garnick; Marc B.	Brookline	MA
Gefter; Malcolm L.	Lincoln	MA
Hundal; Arvind	Brighton	MA
Kasman; Laura	Athens	GA
Musso; Gary	Hopkinton	MA
Signer; Ethan R.	Cambridge	MA
Wakefield; James	Brookline	MA
Reed; Michael	Marietta	GA
Molineaux; Susan	Brookline	MA
Kubasek; William	Belmont	MA
Chin; Joseph	Salem	MA
Lee; Jung-Ja	Wayland	MA
Kelley; Michael	Arlington	MA

US-CL-CURRENT: 514/2; 514/12, 514/14, 530/324, 530/326

## ABSTRACT:

Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural .beta. amyloid peptides (.beta.-AP). In a preferred embodiment, the .beta. amyloid modulator compounds of the invention are comprised of an A.beta. aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural .beta. amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural .beta.-AP aggregation when the natural .beta.-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

10 Claims, 10 Drawing figures  
Exemplary Claim Number: 5  
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	---------

☐ 10. Document ID: US 5744131 A

L4: Entry 10 of 29

File: USPT

Apr 28, 1998

US-PAT-NO: 5744131

DOCUMENT-IDENTIFIER: US 5744131 A

TITLE: Sequence-directed DNA-binding molecules compositions and methods

DATE-ISSUED: April 28, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------



Edwards; Cynthia A.	Menlo Park	CA
Fry; Kirk E.	Palo Alto	CA
Cantor; Charles R.	Boston	MA
Andrews; Beth M.	Maynard	MA

US-CL-CURRENT: 424/78.08; 436/501, 514/1

## ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

3 Claims, 48 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 33

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

## □ 11. Document ID: US 5738990 A

L4: Entry 11 of 29

File: USPT

Apr 14, 1998

US-PAT-NO: 5738990

DOCUMENT-IDENTIFIER: US 5738990 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Sequence-directed DNA-binding molecules compositions and methods

DATE-ISSUED: April 14, 1998

## INVENTOR- INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/24.1

## ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic

or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

5 Claims, 48 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 33

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 12. Document ID: US 5726014 A

L4: Entry 12 of 29

File: USPT

Mar 10, 1998

US-PAT-NO: 5726014  
DOCUMENT-IDENTIFIER: US 5726014 A

TITLE: Screening assay for the detection of DNA-binding molecules

DATE-ISSUED: March 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Watertown	MA		
Turin; Lisa M.	Berkeley	CA		

US-CL-CURRENT: 435/6; 435/91.2, 436/501

ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

19 Claims, 72 Drawing figures

Exemplary Claim Number: 1  
Number of Drawing Sheets: 47

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 13. Document ID: US 5716780 A

L4: Entry 13 of 29

File: USPT

Feb 10, 1998

US-PAT-NO: 5716780  
DOCUMENT-IDENTIFIER: US 5716780 A

TITLE: Method of constructing sequence-specific DNA-binding molecules

DATE-ISSUED: February 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Watertown	MA		

US-CL-CURRENT: 435/6; 436/501

ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

9 Claims, 48 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 33

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 14. Document ID: US 5716619 A

L4: Entry 14 of 29

File: USPT

Feb 10, 1998

US-PAT-NO: 5716619  
DOCUMENT-IDENTIFIER: US 5716619 A

TITLE: Treatment of type 2 diabetes mellitus

DATE-ISSUED: February 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J.S.	Woodstock			GB2
Greene, Jr.; Howard	Rancho Santa Fe	CA		

US-CL-CURRENT: 424/130.1; 424/131.1, 424/139.1, 424/141.1, 424/145.1, 424/156.1, 514/12, 514/866

ABSTRACT:

Antibody methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics, are disclosed. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP), or biologically active sub-peptides thereof. Inhibitors include antibodies directed to amylin and amylin agonist active sites. Other antagonists include anti-idiotypic antibodies directed to antibodies directed to amylin.

8 Claims, 0 Drawing figures  
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 15. Document ID: US 5693463 A

L4: Entry 15 of 29

File: USPT

Dec 2, 1997

US-PAT-NO: 5693463  
DOCUMENT-IDENTIFIER: US 5693463 A

TITLE: Method of ordering sequence binding preferences of a DNA-binding molecule

DATE-ISSUED: December 2, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		

US-CL-CURRENT: 435/6; 435/7.23, 536/23.1

## ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

3 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 33

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 16. Document ID: US 5686411 A

L4: Entry 16 of 29

File: USPT

Nov 11, 1997

US-PAT-NO: 5686411

DOCUMENT-IDENTIFIER: US 5686411 A

TITLE: Amylin agonist peptides and uses therefor

DATE-ISSUED: November 11, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gaeta; Laura S. L.	Foster City	CA		
Jones; Howard	Poway	CA		
Albrecht; Elisabeth	San Diego	CA		

US-CL-CURRENT: 514/12; 514/2, 514/4, 514/866, 530/324

## ABSTRACT:

Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.

45 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 17. Document ID: US 5641744 A

L4: Entry 17 of 29

File: USPT

Jun 24, 1997

US-PAT-NO: 5641744

DOCUMENT-IDENTIFIER: US 5641744 A

TITLE: Treatment of diabetes mellitus

DATE-ISSUED: June 24, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Woodstock			GB2

US-CL-CURRENT: 514/4; 514/12, 530/303

## ABSTRACT:

The present invention relates to methods of preparing a product or a composition containing amylin or amylin with insulin for treating diabetes mellitus.

17 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 18. Document ID: US 5578444 A

L4: Entry 18 of 29

File: USPT

Nov 26, 1996

US-PAT-NO: 5578444

DOCUMENT-IDENTIFIER: US 5578444 A

TITLE: Sequence-directed DNA-binding molecules compositions and methods

DATE-ISSUED: November 26, 1996

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		
Turin; Lisa M.	Redwood City	CA		
Fry; Kirk E.	Palo Alto	CA		

US-CL-CURRENT: 435/6; 435/7.23, 536/23.1

## ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

15 Claims, 71 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 48

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 19. Document ID: US 5424221 A

L4: Entry 19 of 29

File: USPT

Jun 13, 1995

US-PAT-NO: 5424221

DOCUMENT-IDENTIFIER: US 5424221 A

\*\* See image for Certificate of Correction \*\*

TITLE: Kit for detection of islet amyloid polypeptide (IAPP)

DATE-ISSUED: June 13, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Westermarck; Per	Balinge			SE
Johnson; Kenneth H.	Minneapolis	MN		

US-CL-CURRENT: 436/518; 435/7.92, 435/7.94, 435/7.95, 435/975, 436/501, 436/533, 436/548, 530/387.1, 530/387.9, 530/388.24

ABSTRACT:

This invention is directed to kits for the detection of human islet amyloid polypeptide (IAPP) comprising (a) purified preparations of antibodies which react specifically with insulin or calcitonin gene-related peptides and (b) a preselected amount of human islet amyloid polypeptide which is essentially free of islet amyloid, which polypeptide is one subunit of islet amyloid and which is prepared by depolymerizing human islet amyloid; or a preselected amount of human islet amyloid polypeptide which is essentially free of islet amyloid and has the amino acid sequence: lys-cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Se r-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr.

13 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 20. Document ID: US 5298605 A

L4: Entry 20 of 29

File: USPT

Mar 29, 1994

US-PAT-NO: 5298605

DOCUMENT-IDENTIFIER: US 5298605 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Antibodies to islet amyloid polypeptide (IAPP) and subunits thereof

DATE-ISSUED: March 29, 1994

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Westermarck; Per	Balinge			SE
Johnson; Kenneth H.	Minneapolis	MN		

US-CL-CURRENT: 530/387.9; 530/324, 530/327, 530/388.2, 530/388.24, 530/389.2, 530/391.1, 530/808, 530/845

## ABSTRACT:

This invention is directed to antibodies which react with human islet amyloid polypeptide and which do not significantly react with insulin or calcitonin gene-related peptides. Preparations of antibodies are provided which bind to islet amyloid polypeptide (IAPP) which is substantially free of islet amyloid, and when isolated from humans, has the following amino acid sequence in positions 1-37:

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val- His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly- Ser-Asn-Thr-Tyr.

11 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 21. Document ID: US 5281581 A

L4: Entry 21 of 29

File: USPT

Jan 25, 1994

US-PAT-NO: 5281581

DOCUMENT-IDENTIFIER: US 5281581 A

TITLE: Treatment of insulin resistance

DATE-ISSUED: January 25, 1994



## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Woodstock			GB2
Greene, Jr.; Howard	Rancho Sante Fe	CA		

US-CL-CURRENT: 514/12; 424/131.1, 424/143.1, 514/13, 514/14, 514/15

## ABSTRACT:

Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP), or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotypic antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.

4 Claims, 0 Drawing figures  
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	IMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 22. Document ID: US 5276059 A

L4: Entry 22 of 29

File: USPT

Jan 4, 1994

US-PAT-NO: 5276059

DOCUMENT-IDENTIFIER: US 5276059 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Inhibition of diseases associated with amyloid formation

DATE-ISSUED: January 4, 1994

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Caughey; Byron	Hamilton	MT		
Race; Richard	Hamilton	MT		

US-CL-CURRENT: 514/647

## ABSTRACT:

The invention provides a method of treating a mammal having a condition associated with formation of amyloidogenic protein without deposition of amyloid plaques. This treatment includes administering to the mammal a pharmacologically effective amount of Congo Red or a pharmaceutically acceptable salt or derivative thereof to interfere with amyloidogenic protein formation or to destabilize amyloidogenic protein structures already formed in said mammal. The invention also provides a

method of treating a mammal having a condition associated with deposition of amyloidogenic protein in plaques, and a method of inhibiting the transformation of PrP-sen to PrP-res in a tissue culture sample containing PrP-sen.

34 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 23. Document ID: US 5266561 A

L4: Entry 23 of 29

File: USPT

Nov 30, 1993

US-PAT-NO: 5266561

DOCUMENT-IDENTIFIER: US 5266561 A

TITLE: Treatment of type 2 diabetes mellitus

DATE-ISSUED: November 30, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Woodstock			GB
Greene, Jr.; Howard	Rancho Santa Fe	CA		

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 514/16, 530/307, 530/324, 530/325,  
530/326, 530/327, 530/328, 530/329

ABSTRACT:

Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP), or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotypic antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.

4 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 24. Document ID: US 5260275 A

L4: Entry 24 of 29

File: USPT

Nov 9, 1993

US-PAT-NO: 5260275  
DOCUMENT-IDENTIFIER: US 5260275 A

TITLE: Hypoglycemics

DATE-ISSUED: November 9, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Solana Beach	CA		
Moore; Candace X.	San Diego	CA		

US-CL-CURRENT: 514/12; 514/13, 514/866

ABSTRACT:

Non-insulin dependent, or type 2, diabetes mellitus in a patient is treated by administering to the patient a hypoglycemic agent that enhances plasma concentrations of amylin and a therapeutically effective amount of an amylin antagonist. Hypoglycemic agents which enhance plasma concentrations of amylin can be sulfonylureas such as glibenclamide and tolbutamide. Amylin antagonists can be amylin 8-37 and CGRP 8-37. Administration of the amylin antagonist in conjunction with the hypoglycemic agent also enhances the blood glucose lowering effects of the hypoglycemic agent.

13 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 25. Document ID: US 5175145 A

L4: Entry 25 of 29

File: USPT

Dec 29, 1992

US-PAT-NO: 5175145  
DOCUMENT-IDENTIFIER: US 5175145 A

TITLE: Treatment of diabetes mellitus with amylin agonists

DATE-ISSUED: December 29, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Woodstock			GB2

US-CL-CURRENT: 514/4; 514/12

ABSTRACT:

Novel methods for treating diabetes mellitus and hyperglycemia are described which comprise administering to a diabetic or hypoglycemic subject an amount of an amylin

agonist effective to induce amylin activity in said subject. Various amylin agonist compounds, and therapeutic methods utilizing such compounds, are also disclosed.

25 Claims, 1 Drawing figures  
Exemplary Claim Number: 1  
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 26. Document ID: US 5164295 A

L4: Entry 26 of 29

File: USPT

Nov 17, 1992

US-PAT-NO: 5164295

DOCUMENT-IDENTIFIER: US 5164295 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds

DATE-ISSUED: November 17, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kisilevsky; Robert	Kingston			CA
Szarek; Walter A.	Kingston			CA
Narindrasorasak; Suree	Kingston			CA

US-CL-CURRENT: 435/7.8; 435/7.92, 435/7.93, 435/7.95, 436/501

ABSTRACT:

A method for identifying compounds useful for treating patients with amyloidosis is disclosed. Compounds are screened according to the present invention to determine their ability to modulate the affinity between amyloid protein and proteins of the extracellular matrix.

4 Claims, 0 Drawing figures  
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 27. Document ID: US 5124314 A

L4: Entry 27 of 29

File: USPT

Jun 23, 1992

US-PAT-NO: 5124314

DOCUMENT-IDENTIFIER: US 5124314 A

TITLE: Pharmaceutical compositions containing amylin

DATE-ISSUED: June 23, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Solana Beach	CA		

US-CL-CURRENT: 514/4; 514/12, 514/13, 514/14, 514/15, 514/16, 514/17, 514/3

ABSTRACT:

The present invention relates to pharmaceutical compositions for use in treating diabetes Mellitus or hypoglycemia containing Amylin as the effective additive.

9 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

☐ 28. Document ID: US 5116948 A

L4: Entry 28 of 29

File: USPT

May 26, 1992

US-PAT-NO: 5116948

DOCUMENT-IDENTIFIER: US 5116948 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Preparations of islet amyloid polypeptide (IAPP) and antibodies to IAPP

DATE-ISSUED: May 26, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Westermarck; Per	Dalinge			SE
Johnson; Kenneth H.	Minneapolis	MN		

US-CL-CURRENT: 530/324; 530/303, 530/866

ABSTRACT:

Islet Amyloid Polypeptide substantially free of Islet Amyloid which can be isolated from Islet Amyloid of different mammals and when isolated from humans it has the following amino acid sequence in positions 1-37: ##STR1##

1 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	--------

## 29. Document ID: US 5112945 A

L4: Entry 29 of 29

File: USPT

May 12, 1992

US-PAT-NO: 5112945

DOCUMENT-IDENTIFIER: US 5112945 A

\*\* See image for Certificate of Correction \*\*TITLE: Preparation of islet amyloid polypeptides (IAPP) and antibodies to IAPP

DATE-ISSUED: May 12, 1992

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Westermarck; Per	Dalinge			SE
Johnson; Kenneth H.	Minneapolis	MN		

US-CL-CURRENT: 530/324; 530/303, 530/327, 530/845

## ABSTRACT:

Subunits of the full length 37 amino acid residue human Islet Amyloid Polypeptide, and feline Islet Amyloid Polypeptide essentially free of unpolymerized amyloid are provided. Islet Amyloid Polypeptide (IAPP) may be isolated and purified from amyloid fibrils using depolymerizing agent and chromatographic techniques. The sequences of the purified Islet Amyloid Polypeptides have been determined. Purified Islet Amyloid Polypeptides are suitable for induction of anti-IAPP antibodies.

4 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Term	Documents
@PD	12125024
(3 AND (@PD < "20000504")).PGPB,USPT,USOC.	29
(L3 AND @PD<20000504 ).PGPB,USPT,USOC.	29

Display Format: -

Change Format

Previous Page

Next Page

Go to Doc#